Andrea S. Blevins Primeau, PhD, MBA

Patients with thoracic cancer and COVID-19 had a high mortality rate and were frequently not offered intensive care in the global TERAVOLT registry.

Nearly one-third of cancer survivors or their partners reported job lock—remaining employed due to concern of losing health insurance.

A higher dose of anti-CD19 CAR-T resulted in similar toxicities, but higher ORR and longer PFS, compared with a lower dose in patients with relapsed/refractory CLL.

Anticancer treatment was shown to influence genomic landscapes among patients with advanced cancer.

A ctDNA test identified patients who would develop early relapse after surgical resection of stage I to III NSCLC.

A first-in-human, universal CAR-T therapy was tolerable and showed activity against relapsed/refractory T-ALL in a phase 1 study.

A novel, bispecific CD19/CD22 CAR-T therapy was tolerable and led to responses in a phase 1, dose-escalating study.

Payer adoption of utilization management increased the uptake of guideline-recommended hypofractionated radiotherapy for eligible patients with early-stage breast cancer.

The incidence of osimertinib-associated grade 3 or higher cardiac adverse events was 4.9% in a retrospective NSCLC population.

A subset of testicular cancer survivors experience persistent, treatment-related, long-term adverse health outcomes that affect their ability to work.